An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated improvements in a respiratory health measure for patients with idiopathic ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients with idiopathic pulmonary fibrosis in Korea. Recently, the number of patients ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...